Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...
Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...
Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...
The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...
An estimated 2.9 million people worldwide live with multiple sclerosis, a chronic and lifelong disease. It disproportionately affects women.
Roche Holding's Genentech unit said the Food and Drug Administration approved its twice-yearly, subcutaneous injection treatment for patients with two types of multiple sclerosis. The treatment, ...
China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal ...
Multiple sclerosis (MS) is a disabling ... or Class III/IV heart failure or have a presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or ...
Ocrevus Zunovo can be administrated by providers twice a year with a 10-minute subcutaneous injection. Ocrevus Zunovo will be ...
A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...
Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback